Epigenomics AG Announces Departure of Executive Board Member Jens Ravens

On April 30, 2024, Jens Ravens will officially step down from his role as a member of the Executive Board at Epigenomics AG. This departure comes following the completion of a significant asset transfer to New Day Diagnostics LLC. Ravens has been notably active in pivotal company phases, contributing to both the restructuring set in motion in early 2023 and the eventual sale of the company’s assets.

Dr. Helge Lubenow expressed gratitude towards Ravens for his leadership during challenging times, securing the company's future through these strategic moves. The sale, favored by the majority at the Extraordinary Shareholders’ Meeting, is seen as a valuable strategy for shareholder value in current circumstances. Ravens' tenure as Chief Financial Officer began in February 2022, taking on the additional role of sole Executive Board member following CEO Greg Hamilton’s departure in June 2023.

Following his exit, Hansjörg Plaggemars is set to become the sole Executive Board member starting May 1, 2024. This leadership change marks a new chapter for Epigenomics as it continues to navigate through its strategic realignments.